Abstral Growth and a Warrant Valuation Benefit Shrink Galena's Q1 Loss by 73%

Highly volatile and controversial small-cap biopharmaceutical Galena Biopharma (NASDAQ: GALE  ) gave optimists a reason to cheer after the closing bell this evening by delivering top- and bottom-line improvements with the release of its first-quarter results.

For the quarter, Galena reported revenue of $2.2 million that was entirely from the sale of its breakthrough cancer pain medication Abstral. Galena recorded no revenue in the year-ago quarter, and Abstral's $2.2 million in sales represents a nearly 70% sequential improvement over the fourth quarter.

On the clinical front Galena announced that enrollment in its critical phase 3 PRESENT trial for cancer immunotherapy vaccine NeuVax is still ongoing, but on track to be completed by the end of this year.

Operating expenses for the quarter soared as the company moves select clinical programs into late-stage development and as it beefs up its marketing and sales staff in lieu of Abstral's commercialization. Research and development expenses jumped 33% from the prior-year period to $6.8 million while selling, general and administrative expenses soared 346% to a matching $6.8 million.

Net loss for the quarter dipped significantly as the company benefited from a $9.8 million change in warrant value compared to a loss of $5 million in the year-ago quarter. The end result was a net loss of $2.5 million, or $0.02 per share, from $9.3 million, or $0.11 per share, a 73% reduction.

Looking ahead, Galena Biopharma stuck by its full-year revenue forecast for Abstral of $11 million-$15 million, although it offered no bottom-line guidance. 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2946268, ~/Articles/ArticleHandler.aspx, 7/28/2014 9:23:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement